

TAYSIDE PRESCRIBER

Tayside DTC Supplement No 83

October 2008

Produced by NHS Tayside Drug and Therapeutics Committee Medicines Advisory Group (MAG)

SMC Advice issued in October 2008

Medicine	Indication	Local recommendation category	Comments and useful links
Capecitabine (Xeloda [®])	Metastatic colorectal cancer	HOSPITAL ONLY Recommended within specialist pathway	SMC advice SPC link Its use will be incorporated into current treatment protocols
Cinacalcet (Mimpara [®]) - Non submission	Reduction of hypercalcaemia in patients with primary hyperparathyroidism (HPT) for whom parathyroidectomy is not clinically appropriate or is contraindicated	Not recommended	SMC advice
Dexrazoxane (Savene [®]) – Re-submission	Treatment of anthracycline extravasation	Not recommended	SMC advice
Duloxetine (Cymbalta [®]) - Non submission	Generalised anxiety disorder	Not recommended	SMC advice
Fosaprepitant dimeglumine (Ivemend [®])	Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy	HOSPITAL ONLY Recommended for use in very limited circumstances within specialist pathway	SMC advice SPC link
Maraviroc (Celsentri [®]) - Resubmission	In combination with other antiretroviral medicinal products for treatment experienced adult patients infected with only CCR5-tropic HIV-1 detectable	Not recommended	SMC advice
Pegylated liposomal doxorubicin (Caelyx [®])	In combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.	Not recommended	SMC advice
Salbutamol sulphate (Salbulin MDPI Novoliser [®]) - Abbreviated submission	Asthma	Pending Respiratory Formulary Group decision	SMC advice SPC link
Sitagliptin (Januvia [®])	Patients with type 2 diabetes mellitus to improve glycaemic control in combination with a sulphonylurea with or without metformin	Non-formulary medicine	SMC advice SPC link

Click here for [October 08](#) SMC briefing note

TAPG Update

3	Respiratory System	3.1 Bronchodilators	Link to BTS/SIGN guideline updated. Dose information for each preparation updated to clarify whether used in asthma or COPD, or both. Link to MHRA Drug Safety Update (Oct 2008) on theophylline containing medicines available OTC inserted. Compound bronchodilator preparations – note added on use of nebulised salbutamol and ipratropium or combined as Combivent®.
		3.2 Inhaled corticosteroids	Note added on inhaled steroids in COPD. Glenil Modulite® ▼ dose information expanded to include use of Volumatic® spacer at required doses/ages. Information on use of inhaled steroids and long-acting bronchodilator in COPD expanded. Information on licensing of combined inhaled steroids and long-acting bronchodilators added.
		3.3 Cromoglycate related therapy and leukotriene receptor antagonists	Dose information for montelukast amended to be in line with manufacturers product licence. Guidance on prescribing of montelukast chewable tablets and granules added as per SMC advice .
		3.4 Antihistamines and allergic emergencies	Minor changes to dose information for loratadine and alimemazine.
		3.6 Oxygen	Additions to information on patients with type 1 respiratory failure and changes to wording throughout.
3	Respiratory System Guidelines	Guidance on Inhaler Devices 12 years+	Volumatic® removed from spacer device compatibility table for Atrovent® as not compatible. Inspiratory flow rates listed for use of Turbohaler® removed and replaced with a general statement on dry powder inhalers. Spiriva ▼ Respimat® inhaler* added as 'Other inhaled devices'.
		Emergency Management of Acute Asthma for under 12 years	Replaced with a link to Management of acute asthma in children aged over 2 years and Management of acute asthma in children under 2 years from BTS/SIGN No.101 quick reference guide (pages 15 & 16), and link to Management of acute asthma in children in general practice from BTS/SIGN No.101 full guideline (Annex 5, page 99).
		Emergency Management of Acute Asthma in Adults and Children over 12 years	Replaced with a link to the BTS/SIGN No.101 quick reference guide which includes chart on Management of Acute Asthma in adults (pages 13 & 14), and link to the BTS/SIGN No.101 full guideline (Annex 2, page 96) which includes chart on Management of acute severe asthma in adults in general practice.
		Notes on Managing Chronic Asthma	Note on higher doses of inhaled steroids possibly required in smokers/ex-smokers. Link to BTS/SIGN guideline updated.
		Managing Chronic Asthma in Children under 12 years	Replaced with link to Summary of stepwise management in children aged 5-12 years and in children less than 5 years from BTS/SIGN No.101 quick reference guide (pages 10 & 11).
		Managing Chronic Asthma in Children over 12 years	Replaced with link to Summary of stepwise management in adults from BTS/SIGN No.101 quick reference guide (page 9).
		Chronic Obstructive Pulmonary Disease (COPD) Guidelines	Link to Guidance on Smoking Cessation in Tayside inserted. Further information on use of inhaled steroids in COPD added in combination with a long-acting bronchodilator. Chart on bronchodilator therapy for replaced with updated chart on pharmacological therapy.
		Anaphylaxis Guidelines	Replaced with Resuscitation Council (UK) Anaphylaxis guidelines and Anaphylaxis algorithm .

* SMC accepted medicine

ACCESSING THE TAYSIDE AREA PRESCRIBING GUIDE (TAPG)

Following the introduction of the new Staffnet, please note that the Tayside Area Prescribing Guide can now be found through the undernoted pathway.

From the home page of Staffnet, click on Clinical Information which can be located on the left hand side as shown below:

[Working For Us](#)
[How We Work](#)
[Safe & Effective Working](#)
[Healthy Working Lives](#)
[Clinical Information](#) ←
[Emergency Planning](#)
[TREATS](#)
[Internal Links](#)
[External Links](#)

From here, click on the Tayside Area Prescribing Guide which can be located on the right hand side under 'Quick Links' as shown below:

Quick Links

→ [Central Vision](#)
[eBNF](#)
[Tayside Area Prescribing Guide](#)

NB: For easy access at ward level save to your desktop.

[Forthcoming SMC Advice](#)

Local implementation of SMC recommendations is taken forward by the Tayside Medicines Governance Unit. This bulletin is based on evidence available to the Tayside Medicines Governance Unit at time of publication and is covered by the Disclaimer and Terms & Conditions of use and access to the NHS Tayside Drug and Therapeutics Committee website (www.nhstaysideadtc.scot.nhs.uk).